North America Newborn Screening Market - Industry Trends and Forecast to 2026

  • In Vitro Diagnostics
  • Published Report
  • Oct 2019
  • North America
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 25

North America Newborn Screening Market By Test Type (Dried Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test), Product Type (Instruments, Reagents and Assay Kits), Technology (Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, DNA-Based Assays), Disease Type (Critical Congenital Heart Diseases, Newborn Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, Others), End User (Hospital, Paediatric Clinics, Clinics), Country (U.S., Canada, Mexico) - Industry Trends and Forecast to 2026

North America market for newborn screening is considered to be one of the most expanding markets in the global healthcare industry. Newborn screening is the testing that diagnoses harmful and fatal disorders in newborns which can adversely affect their long term health. The newborn screening tests can detect around thirty metabolic and genetic diseases and some common are phenylketonuria (PKU), congenital hypothyroidism (CH), galactosemia (GAL), and sickle cell disease. Increased government initiatives to aware people regarding newborn screening are playing a vital role in expansion of newborn screening market. Newborn screening is a mandatory test in over 60 countries including U.S.

North America newborn screening market is projected to register a healthy CAGR in the forecast period of 2019 to 2026.

SegmentationNorth America Newborn Screening Market

North America newborn screening market is segmented into five notable segments which are test type, product type, technology, disease type and end user.

  • On the basis of test type, the market is segmented into dried blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test.
  • On the basis of product type, the market is segmented into instruments, reagents & assay kits.
  • On the basis of technology, the market is segmented into tandem mass spectrometry, hearing screen technology, pulse oximetry screening technology, immunoassays and enzymatic assays, electrophoresis, DNA-based assays.
  • On the basis of disease type, the market is segmented into phenylketonuria (PKU), cystic fibrosis (CF), sickle cell disease, newborn hearing loss, critical congenital heart diseases, maple syrup urine disease, others.
  • On the basis of end user, the market is segmented into pediatric clinics, hospital, clinics.

Competitive Analysis: North America Newborn Screening Market

Some of the major players operating in the North America newborn screening market are PerkinElmer Inc., Natus Medical Incorporated, Trivitron Healthcare, Baebies, Inc., Bio-Rad Laboratories, Inc., Danahar, Hill-Rom Services Inc., Intelligent Hearing Systems, Interacoustics A/S, Masimo, Medtronic, Otodynamics Ltd, Vivosonic Inc., ZenTech S.A., among others.

Recent Developments

  • In September 2019, Baebies, Inc. attended a symposium organised on Study of Inborn Error Metabolism. The company will discuss about its product Seeker. It will help in enhancing the market share and market value of the company.
  • In June 2019, Interacoustics A/S modified Sera and HearSIM by incorporating it with distortion product otoacoustic emissions (DPOAE). With this modification Sera combines DPOAE, TEOAE and automated ABR screening in a single handheld rechargeable device. This improvement in the product enhances the product portfolio of the company.
  • In December 2017, Interacoustics A/S modified Sera by incorporating it with distortion product otoacoustic emissions (DPOAE). With this modification Sera combines DPOAE, TEOAE and automated ABR screening in a single handheld rechargeable device. This improvement in the product enhances the product portfolio of the company.

Research Methodology: North America Newborn Screening Market

Primary Respondents: Key Opinion Leaders (KOL’s): Doctors, Nurses, Research Institutes and Medical Professionals. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.


SKU-

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA NEWBORN SCREENING MARKET

1.4 LIMITATIONS

1.5 CURRENCY AND PRICING

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 SECONDARY SOURCES

2.7 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING PREVALENCE OF NEWBORN SCREENING

3.1.2 GROWTH IN NEONATAL DISEASES

3.1.3 INCREASED GOVERNMENT INITIATIVES

3.1.4 TECHNOLOGICAL ADVANCEMENTS IN SCREENING

3.2 RESTRAINTS

3.2.1 STRINGENT REGULATORY POLICIES

3.2.2 HIGH COST OF AUTOMATED DEVICES

3.3 OPPORTUNITIES

3.3.1 NEXT-GENERATION SEQUENCING TECHNOLOGY FOR NEWBORN SCREENING

3.3.2 EMERGING MARKET

3.4 CHALLENGES

3.4.1 SOCIO ECONOMIC BARRIERS

3.4.2 LACK OF SKILLED PROFESSIONALS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 NORTH AMERICA NEWBORN SCREENING MARKET, BY TEST TYPE

6.1 OVERVIEW

6.2 DRIED BLOOD SPOT TEST

6.3 HEARING SCREEN TEST

6.4 CRITICAL CONGENITAL HEART DISEASES (CCHD) TEST

7 NORTH AMERICA NEWBORN SCREENING MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 INSTRUMENTS

7.2.1 NEWBORN DISORDER SCREENING INSTRUMENTS

7.2.2 NEWBORN HEARING SCREENING INSTRUMENTS

7.2.3 PULSE OXIMETER

7.3 REAGENTS AND ASSAY KITS

8 NORTH AMERICA NEWBORN SCREENING MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 TANDEM MASS SPECTROMETRY

8.3 HEARING SCREEN TECHNOLOGY

8.4 PULSE OXIMETRY SCREENING TECHNOLOGY

8.5 IMMUNOASSAYS AND ENZYMATIC ASSAYS

8.6 ELECTROPHORESIS

8.7 DNA-BASED ASSAYS

9 NORTH AMERICA NEWBORN SCREENING MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 CRITICAL CONGENITAL HEART DISEASES

9.3 NEWBORN HEARING LOSS

9.4 SICKLE CELL DISEASE

9.5 PHENYLKETONURIA (PKU)

9.6 CYSTIC FIBROSIS (CF)

9.7 MAPLE SYRUP URINE DISEASE

9.8 OTHERS

10 NORTH AMERICA NEWBORN SCREENING MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 PEDIATRIC CLINICS

10.4 CLINICS

11 NORTH AMERICA NEWBORN SCREENING MARKET, BY GEOGRAPHY

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA NEWBORN SCREENING MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 COMPANY PROFILES

13.1 PERKINELMER INC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 PRODUCT PORTFOLIO

13.1.4 RECENT DEVELOPMENTS

13.2 NATUS MEDICAL INCORPORATED

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENTS

13.3 TRIVITRON HEALTHCARE

13.3.1 COMPANY SNAPSHOT

13.3.2 PRODUCT PORTFOLIO

13.3.3 RECENT DEVELOPMENTS

13.4 BAEBIES, INC.

13.4.1 COMPANY SNAPSHOT

13.4.2 PRODUCT PORTFOLIO

13.4.3 RECENT DEVELOPMENTS

13.5 BIO-RAD LABORATORIES, INC.

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENT

13.6 DANAHER

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENT

13.7 HILL-ROM SERVICES INC.

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENT

13.8 INTELLIGENT HEARING SYSTEMS

13.8.1 COMPANY SNAPSHOT

13.8.2 PRODUCT PORTFOLIO

13.8.3 RECENT DEVELOPMENT

13.9 INTERACOUSTICS A/S

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENTS

13.1 MASIMO

13.10.1 COMPANY SNAPSHOT

13.10.2 REVENUE ANALYSIS

13.10.3 PRODUCT PORTFOLIO

13.10.4 RECENT DEVELOPMENT

13.11 MEDTRONIC

13.11.1 COMPANY SNAPSHOT

13.11.2 REVENUE ANALYSIS

13.11.3 PRODUCT PORTFOLIO

13.11.4 RECENT DEVELOPMENT

13.12 OTODYNAMICS LTD

13.12.1 COMPANY SNAPSHOT

13.12.2 PRODUCT PORTFOLIO

13.12.3 RECENT DEVELOPMENTS

13.13 VIVASONIC INC.

13.13.1 COMPANY SNAPSHOT

13.13.2 PRODUCT PORTFOLIO

13.13.3 RECENT DEVELOPMENTS

13.14 ZENTECH S.A.

13.14.1 COMPANY SNAPSHOT

13.14.2 PRODUCT PORTFOLIO

13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

TABLE 1 NEWBORN SCREENING PROGRAM (2015 & 2016) IN THE U.S.

TABLE 2 NEONATAL MORTALITY RATE (DEATHS PER 1,000 LIVE BIRTHS), IN BETWEEN 2015 -2018

TABLE 3 PREVALENCE OF DISORDERS AMONG FILIPINO NEWBORNS (1996-2016)

TABLE 4 NUMBER OF BIRTHS IN NORTHERN HEMISPHERE (2018)

TABLE 5 PREVALENCE OF DISORDERS AMONG NORTHERN HEMISPHERE (2018)

TABLE 6 COSTS OF NEXT GENENARATION SEQUENCING DEVICES (USD MILLION)

TABLE 7 HEALTHCARE EXPENDITURE IN ASIA PACIFIC (USD MILLION)

TABLE 8 COMPARISON OF THE ECONOMIC PROSPERITY AND ANNUAL PERCENTAGE OF NEWBORN BABIES SCREENED IN SELECTED DEVELOPING NATIONS

TABLE 9 NORTH AMERICA NEWBORN SCREENING MARKET, BY TEST TYPE, 2017-2026 (USD MILLION)

TABLE 10 NORTH AMERICA DRIED BLOOD SPOT TEST IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 NORTH AMERICA HEARING SCREEN TEST IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 12 NORTH AMERICA CRITICAL CONGENITAL HEART DISEASES TEST IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 NORTH AMERICA NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 14 NORTH AMERICA PRODUCT IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 NORTH AMERICA INSTRUMENTS IN NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 16 NORTH AMERICA REAGENTS AND ASSAY KITS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 NORTH AMERICA NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2017-2026 (USD MILLION)

TABLE 18 NORTH AMERICA TANDEM MASS SPECTROMETRY IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 NORTH AMERICA HEARING SCREEN TECHNOLOGY IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 NORTH AMERICA PULSE OXIMETRY SCREENING TECHNOLOGY IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 NORTH AMERICA IMMUNOASSAYS AND ENZYMATIC ASSAYS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 NORTH AMERICA ELECTROPHORESIS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 NORTH AMERICA DNA-BASED ASSAYS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 NORTH AMERICA NEWBORN SCREENING MARKET, BY DISEASE TYPE, 2017-2026 (USD MILLION)

TABLE 25 NORTH AMERICA CRITICAL CONGENITAL HEART DISEASES IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 NORTH AMERICA NEWBORN HEARING LOSS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 27 NORTH AMERICA SICKLE CELL DISEASE IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 28 NORTH AMERICA PHENYLKETONURIA IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 29 NORTH AMERICA CYSTIC FIBROSIS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 NORTH AMERICA MAPLE SYRUP URINE DISEASE IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 31 NORTH AMERICA OTHERS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 32 NORTH AMERICA NEWBORN SCREENING MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 33 NORTH AMERICA HOSPITAL IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 34 NORTH AMERICA PEDIATRIC CLINICS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 35 NORTH AMERICA CLINICS IN NEWBORN SCREENING MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 NORTH AMERICA NEWBORN SCREENING MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 37 NORTH AMERICA NEWBORN SCREENING MARKET, BY TEST TYPE, 2017-2026 (USD MILLION)

TABLE 38 NORTH AMERICA NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 39 NORTH AMERICA INSTRUMENT IN NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 40 NORTH AMERICA NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2017-2026 (USD MILLION)

TABLE 41 NORTH AMERICA NEWBORN SCREENING MARKET, BY DISEASE TYPE, 2017-2026 (USD MILLION)

TABLE 42 NORTH AMERICA NEWBORN SCREENING MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 43 U.S. NEWBORN SCREENING MARKET, BY TEST TYPE, 2017-2026 (USD MILLION)

TABLE 44 U.S. NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 45 U.S. INSTRUMENT IN NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 46 U.S. NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2017-2026 (USD MILLION)

TABLE 47 U.S. NEWBORN SCREENING MARKET, BY DISEASE TYPE, 2017-2026 (USD MILLION)

TABLE 48 U.S. NEWBORN SCREENING MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 CANADA NEWBORN SCREENING MARKET, BY TEST TYPE, 2017-2026 (USD MILLION)

TABLE 50 CANADA NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 51 CANADA INSTRUMENT IN NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 52 CANADA NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2017-2026 (USD MILLION)

TABLE 53 CANADA NEWBORN SCREENING MARKET, BY DISEASE TYPE, 2017-2026 (USD MILLION)

TABLE 54 CANADA NEWBORN SCREENING MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 55 MEXICO NEWBORN SCREENING MARKET, BY TEST TYPE, 2017-2026 (USD MILLION)

TABLE 56 MEXICO NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 57 MEXICO INSTRUMENT IN NEWBORN SCREENING MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

TABLE 58 MEXICO NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2017-2026 (USD MILLION)

TABLE 59 MEXICO NEWBORN SCREENING MARKET, BY DISEASE TYPE, 2017-2026 (USD MILLION)

TABLE 60 MEXICO NEWBORN SCREENING MARKET, BY END USER, 2017-2026 (USD MILLION)

FIGURE 1 NORTH AMERICA NEWBORN SCREENING MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA NEWBORN SCREENING MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA NEWBORN SCREENING MARKET: RESEARCH SNAPSHOT

FIGURE 4 NORTH AMERICA NEWBORN SCREENING MARKET: NORTH AMERICA VS. REGIONAL ANALYSIS

FIGURE 5 NORTH AMERICA NEWBORN SCREENING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA NEWBORN SCREENING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 DRIVER, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA NEWBORN SCREENING MARKET

FIGURE 8 NEONATAL MORTALITY RATE (PER 1000 LIVE BIRTHS) (2010-2016)

FIGURE 9 NEONATAL MORTALITY RATE (PER 1000 LIVE BIRTHS) (2010-2017)

FIGURE 10 VARIOUS CAUSES OF NEONATAL DEATH WORLDWIDE EACH YEAR

FIGURE 11 HEALTH CARE EXPENDITURE (USD MILLION)

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA NEWBORN SCREENING MARKET AND ASIA- PACIFIC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026

FIGURE 13 GROWTH IN NEONATAL DISEASES IS EXPECTED TO DRIVE THE MARKET FOR NEWBORN SCREENING IN THE FORECAST PERIOD OF 2019 TO 2026

FIGURE 14 DRIED BLOOD SPOT TEST IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA NEWBORN SCREENING MARKET IN 2019

FIGURE 15 NORTH AMERICA NEWBORN SCREENING MARKET: BY TEST TYPE, 2018

FIGURE 16 NORTH AMERICA NEWBORN SCREENING MARKET: BY PRODUCT TYPE, 2018

FIGURE 17 NORTH AMERICA NEWBORN SCREENING MARKET: BY TECHNOLOGY, 2018

FIGURE 18 NORTH AMERICA NEWBORN SCREENING MARKET: BY DISEASE TYPE, 2018

FIGURE 19 NORTH AMERICA NEWBORN SCREENING MARKET: BY END USER, 2018

FIGURE 20 NORTH AMERICA NEWBORN SCREENING MARKET: SNAPSHOT (2018)

FIGURE 21 NORTH AMERICA NEWBORN SCREENING MARKET: BY COUNTRY (2018)

FIGURE 22 NORTH AMERICA NEWBORN SCREENING MARKET: BY COUNTRY (2019 & 2026)

FIGURE 23 NORTH AMERICA NEWBORN SCREENING MARKET: BY COUNTRY (2018 & 2026)

FIGURE 24 NORTH AMERICA NEWBORN SCREENING MARKET: BY TEST TYPE (2019-2026)

FIGURE 25 NORTH AMERICA NEWBORN SCREENING MARKET: COMPANY SHARE 2017 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART